Description
Summary Abstract
Follistatin 344 (FS-344; FST-344; human follistatin isoform 1) is a naturally occurring glycoprotein generated by the alternative splicing of the FST gene to include exon 6, producing a 344-amino-acid preprotein that undergoes signal peptide cleavage to yield the circulating FS-315 isoform. FS-344 is a high-affinity antagonist of multiple TGF-β superfamily members — principally myostatin (growth differentiation factor-8, GDF-8), activin A, and select bone morphogenetic proteins (BMPs) — binding them in the extracellular space to prevent interaction with the activin type IIB receptor (ActRIIB) and downstream Smad2/3 signaling. Transgenic mouse studies report skeletal muscle mass increases of 194–327% versus wild-type, substantially exceeding effects from myostatin knockout alone due to concurrent activin A neutralization. A Phase 1/2a clinical trial using AAV1-FS344 gene therapy in Becker muscular dystrophy (BMD) demonstrated an average 11.5% improvement in the six-minute walk test at six months (p = 0.02).
Clinical Indications
FS-344 research spans skeletal muscle biology, neuromuscular disease, and metabolic research:
- Muscle Hypertrophy and Wasting: Gene delivery of FS-344 produced sustained, dose-dependent muscle mass increases over >2 years in mice with no adverse cardiac pathology or reproductive effects, establishing proof of concept for muscular dystrophy and sarcopenia gene therapy.
- Neuromuscular Disease: AAV1-FS344 in mdx (Duchenne model) and aged mice improved grip strength, tetanic force, and muscle pathology markers (necrosis, inflammation, fibrosis); a Phase 1/2a trial in Becker muscular dystrophy showed functional improvement on the six-minute walk test.
- Metabolic Syndrome / Hepatic Steatosis: Follistatin-derived myostatin inhibition in transgenic models reduced fat mass, improved insulin sensitivity, and prevented high-fat-diet-induced hepatic steatosis — extending applications beyond musculoskeletal research.
Contraindications
- Reproductive Models: FS-288, the membrane-bound isoform, has high affinity for ovarian granulosa cells and suppresses FSH; FS-344 is selected specifically to minimize these effects, but studies involving reproductive endpoints should document isoform identity.
- Broad TGF-β Pathway Studies: FS-344 neutralizes activins, GDF-11, and BMPs in addition to myostatin; experimental designs relying on intact signaling by these ligands will be disrupted at functional FS-344 concentrations.
- Cardiac Hypertrophy Monitoring: While cardiac weight is generally unaffected at doses producing limb muscle hypertrophy, all in vivo protocols should include cardiac assessments, as the dose-response for cardiac versus skeletal muscle effects has been documented to diverge.
Mechanism of Action (MOA)
FS-344 acts as a secreted ligand trap with broad TGF-β superfamily activity:
Myostatin (GDF-8) Neutralization
FS-344 binds myostatin with a dissociation constant of ~12.3 pM, sequestering the GDF-8 dimer in the extracellular space. This prevents myostatin from engaging ActRIIB and triggering Smad2/3 phosphorylation, which would otherwise transcriptionally suppress muscle growth genes. The result is removal of the primary negative regulator of skeletal muscle mass.
Activin A Co-inhibition
Follistatin binds activin A with a dissociation constant of ~1.72 pM — even higher affinity than myostatin binding. Dual neutralization of activin A and myostatin through a single molecule accounts for the 25–30% greater muscle mass increase observed with FS-344 versus myostatin-only inhibitors, implicating activin A as an independent constraint on muscle anabolism.
Satellite Cell Proliferation
BrdU incorporation experiments confirm that FS-344 enhances satellite cell (muscle stem cell) proliferation and differentiation in addition to blocking Smad2/3-mediated growth inhibition. This dual mechanism — removing inhibitory signaling while stimulating the regenerative stem cell compartment — underlies the magnitude of hypertrophic responses observed in vivo.
Heparin-Binding Tissue Localization
FS-344 (processed to FS-315) binds heparan sulfate proteoglycans on muscle cell surfaces, producing primarily local tissue effects after intramuscular delivery. This regional biodistribution limits off-target systemic exposure, distinguishing it from systemically circulating myostatin antibodies and providing a rationale for focal administration in gene therapy protocols.
Key Features & Specifications
Follistatin 344 is provided as a 1 mg lyophilized glycoprotein for in vivo and in vitro muscle biology studies:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| Protein Length | 344 amino acids (preprotein); 315 amino acids after signal peptide cleavage (circulating FS-315) |
| Gene | Human FST gene, exon 6-inclusive isoform |
| Molecular Weight | ~35 kDa (protein core); glycosylated form ~41–44 kDa |
| Primary Targets | Myostatin (GDF-8), activin A, GDF-11, select BMPs |
| Receptor Affinity | Myostatin Kd ~12.3 pM; Activin A Kd ~1.72 pM |
| Synonyms | FS-344; FST-344; follistatin isoform 1; human FS315 precursor |
| Form / Variation | 1 MG Lyophilized Powder (SKU P-010, $88.00) |
Storage, Safety, and Handling
Storage Protocol
Store lyophilized FS-344 at −80 °C for long-term preservation; −20 °C is acceptable for periods up to 6 months. Upon reconstitution in sterile PBS containing 0.1% BSA, store at 4 °C for up to 7 days or aliquot for repeated use. Avoid vortexing; glycoprotein aggregation is irreversible.
Handling & Compliance
Handle with standard protein biology PPE. FS-344 as a recombinant protein is not a regulated substance, but in vivo gene therapy delivery vectors (AAV-FS344) require full IND/GMP compliance. WADA classifies follistatin as a prohibited peptide hormone and growth factor under the S2 category. Institutional review of applicable regulations is required for all in vivo protocols.